Today’s action in FCSC is fully consistent with what I predicted three weeks ago. The company’s newfangled product has no chance of capturing more than a minuscule share of the market for aesthetic medicine.
“The efficient-market hypothesis may be the foremost piece of B.S. ever promulgated in any area of human knowledge!”